Approval · Notice of Compliance 35532 · 2025
SPC-CEFPROZIL: Notice of Compliance 35532
Issued June 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35532
- Date
- June 18, 2025
- Company
- Sun Pharma Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Administrative: Change in product name. Update to package labels
- Canadian reference product
- APO-CEFPROZIL (Apotex Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SPC-CEFPROZIL | 02293528 | Marketed |
| SPC-CEFPROZIL | 02293536 | Marketed |
Medicinal ingredients
- CEFPROZIL MONOHYDRATE 250 MG per TAB
- CEFPROZIL MONOHYDRATE 500 MG per TAB